Home
Juvaris BioTherapeutics

Juvaris BioTherapeutics Market Share Analysis for May 2026

Industry: N/A

Domainjuvaris.com

Year Founded2003

Employees51 - 200

Annual Revenue$15M - $25M

Juvaris BioTherapeutics

Juvaris BioTherapeutics (including company regionals)

juvaris.com

See more website traffic and engagement information

Juvaris BioTherapeutics Revenue up to May 2026 is 15M - 25M

revenue generated by Juvaris BioTherapeutics top domains

Juvaris BioTherapeutics top domains revenue over 3 years

Revenue for Juvaris BioTherapeutics top domains

juvaris.com15M - 25M

See more with Sales Intelligence

Total visits to Juvaris BioTherapeutics's top domains

Understand Juvaris BioTherapeutics market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Juvaris BioTherapeutics's top domains

Analyze Juvaris BioTherapeutics engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Juvaris BioTherapeutics's top domains

See how Juvaris BioTherapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Juvaris BioTherapeutics top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Juvaris BioTherapeutics

These are the website technologies, by industry, used by Juvaris BioTherapeutics top domains

Email Services (1)

Microsoft Exchange Online

News & Signals from Juvaris BioTherapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsJuvaris partnered with Colby Pharmaceutical Company on Sep 9th '11.Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvants, adjuvanted vaccines and immunotherapeutics for infectious diseases and cancer, today announced it has entered into an exclusive license agreement with Colby Pharmaceutical Company for the worldwide development and commercialization of Juvaris' Cationic Lipid-DNA Complex (CLDC) technology and JVRS-100 product candidate, including its intellectual property estate and human clinical development programs, in the field of human (non-animal) health.